Online inquiry

IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14045MR)

This product GTTS-WQ14045MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14045MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1181MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABP 501
GTTS-WQ1338MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ14402MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ11892MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ10178MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ1494MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ77MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ15036MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SRF-231
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW